Literature DB >> 16598205

Outcomes in African Americans and Hispanics with lupus nephritis.

G Contreras1, O Lenz, V Pardo, E Borja, C Cely, K Iqbal, N Nahar, C de La Cuesta, A Hurtado, A Fornoni, L Beltran-Garcia, A Asif, L Young, J Diego, M Zachariah, B Smith-Norwood.   

Abstract

Poor outcomes have been reported in African Americans and Hispanics compared to Caucasians with lupus nephritis. The purpose of this retrospective analysis was to identify independent predictors of outcomes in African Americans and Hispanics with lupus nephritis. In total, 93 African Americans, 100 Hispanics, and 20 Caucasians with a mean age of 28 +/- 13 years and an annual household income of 32.9 +/- 17.3 (in 1000 US dollars) were studied. World Health Organization (WHO) lupus nephritis classes II, III, IV, and V were seen in 9, 13, 52, and 26%, respectively. Important baseline differences were higher mean arterial pressure (MAP) in African Americans compared to Hispanics and Caucasians (107 +/- 19, 102 +/- 15, and 99 +/- 13 mmHg, P < 0.05), and higher serum creatinine (1.66 +/- 1.3, 1.25 +/- 1.0, and 1.31 +/- 1.0 mg/dl, P < 0.025). African Americans had lower hematocrit compared to Hispanics and Caucasians (29 +/- 5, and 31 +/- 6, and 32 +/- 7%, P < 0.05), and lower annual household income (30.8 +/- 14.9, 33.1 +/- 15.9, and 42.2 +/- 29.3 in 1000 US dollars; P < 0.05). Lower prevalence of WHO class IV was seen in Caucasians (30%) compared to Hispanics (57%, P = 0.03) and African Americans (51%, P = 0.09). Development of doubling creatinine or end-stage renal disease was higher in African Americans and Hispanics than in Caucasians (31, 18, and 10%; P < 0.05), as was the development of renal events or death (34, 20, and 10%; P < 0.025). Our results suggest that both biological factors indicating an aggressive disease and low household income are common in African Americans and Hispanics with lupus nephritis, and outcomes in these groups are worse than in Caucasians.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16598205     DOI: 10.1038/sj.ki.5000243

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  57 in total

1.  Clinical presentation and outcomes of childhood-onset membranous lupus nephritis.

Authors:  Maria Pereira; Eyal Muscal; Karen Eldin; M John Hicks; Anna Carmela P Sagcal-Gironella; Marietta DeGuzman; Scott E Wenderfer
Journal:  Pediatr Nephrol       Date:  2017-07-17       Impact factor: 3.714

2.  Ethnic disparity in outcomes for pediatric peritoneal dialysis patients in the ESRD Clinical Performance Measures Project.

Authors:  Meredith A Atkinson; Alicia M Neu; Barbara A Fivush; Diane L Frankenfield
Journal:  Pediatr Nephrol       Date:  2007-09-18       Impact factor: 3.714

3.  ANCA-associated vasculitis in Hispanic Americans: an unrecognized severity.

Authors:  Antoine G Sreih; Ranadeep Mandhadi; Fadi Aldaghlawi; Asad Khan; Vajiha Irshad; Katherine Finn; Joel A Block
Journal:  Clin Rheumatol       Date:  2014-04-22       Impact factor: 2.980

4.  US patients of Hispanic and African ancestry develop lupus nephritis early in the disease course: data from LUMINA, a multiethnic US cohort (LUMINA LXXIV).

Authors:  Paula I Burgos; Gerald McGwin; Guillermo J Pons-Estel; John D Reveille; Graciela S Alarcón; Luis M Vilá
Journal:  Ann Rheum Dis       Date:  2010-07-13       Impact factor: 19.103

5.  Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort.

Authors:  Guillermo J Pons-Estel; Graciela S Alarcón; Leticia Hachuel; Gabriela Boggio; Daniel Wojdyla; Virginia Pascual-Ramos; Enrique R Soriano; Verónica Saurit; Fernando S Cavalcanti; Renato A Guzman; Marlene Guibert-Toledano; Maria J Sauza Del Pozo; Mary-Carmen Amigo; Magaly Alva; Maria H Esteva-Spinetti; Bernardo A Pons-Estel
Journal:  Rheumatology (Oxford)       Date:  2012-03-02       Impact factor: 7.580

6.  Recurrence of lupus nephritis after kidney transplantation.

Authors:  Gabriel Contreras; Adela Mattiazzi; Giselle Guerra; Luis M Ortega; Elaine C Tozman; Hua Li; Leonardo Tamariz; Cristiane Carvalho; Warren Kupin; Marco Ladino; Baudouin LeClercq; Isabel Jaraba; Decio Carvalho; Efrain Carles; David Roth
Journal:  J Am Soc Nephrol       Date:  2010-05-20       Impact factor: 10.121

7.  Efficacy of two cyclophosphamide regimens for the treatment of lupus nephritis in Puerto Ricans: low vs. standard dose.

Authors:  Lesliane E Castro-Santana; Marilú Colón; María J Molina; Vanessa E Rodríguez; Angel M Mayor; Luis M Vilá
Journal:  Ethn Dis       Date:  2010       Impact factor: 1.847

Review 8.  An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases.

Authors:  Alice S Appel; Gerald B Appel
Journal:  Nat Clin Pract Nephrol       Date:  2009-01-27

9.  Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy.

Authors:  Howard A Austin; Gabor G Illei; Michelle J Braun; James E Balow
Journal:  J Am Soc Nephrol       Date:  2009-03-18       Impact factor: 10.121

10.  Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study.

Authors:  David Isenberg; Gerald B Appel; Gabriel Contreras; Mary A Dooley; Ellen M Ginzler; David Jayne; Jorge Sánchez-Guerrero; David Wofsy; Xueqing Yu; Neil Solomons
Journal:  Rheumatology (Oxford)       Date:  2009-11-20       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.